Skip to content
Oligomerix
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Therapeutic Areas
  • Pipeline
    • OLX07010 in Rare Tauopathies
    • OLX07010 Alzheimer’s
  • Technology
    • MOA
    • Patents
  • News & Publications
  • Partners and Collaborators
  • Contact Us
Menu
  • News
  • Presentations
  • Publications
  • Media Coverage
  • Media Kit
  • Archive News

News & Publications

Oligomerix > News & Publications
  •   
  • Print
Oligomerix > News & Publications
+ Expand all
News
Breaking News News

NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough | Neurodegenerative Diagnostic Antibodies

June 10, 2026 Read More
Breaking News News

Oligomerix Completes Ph 1a Clinical Study on OLX-07010

May 19, 2026 Read More
News

Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients

November 18, 2025 Read More
News

Oligomerix Elects New Chairman William Caple to Board of Directors

September 3, 2025 Read More
News

Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases

August 9, 2023 Read More
News

Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010

February 2, 2023 Read More
News

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

January 5, 2023 Read More
News

Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

November 30, 2022 Read More
Media Coverage

Taking a New Approach to Tackle Neurodegenerative Diseases

October 5, 2022 Read More
News

Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010

October 4, 2022 Read More
Presentations
Oligomerix CTAD 2022 Abstract

Overview of the preclinical program for OLX-07010—a novel inhibitor of tau self-association
Abstract: Clinical Trials on Alzheimer's Disease, December 2022

Oligomerix Poster Neuroscience 2022

Pre-clinical evaluation of the exposure and safety of a small molecule inhibitor of tau self-association
Poster: Society for Neuroscience Annual Meeting, November 2022

Preclinical Review and Initial Clinical Plan Overview for Oligomerix's Small Molecule Lead Tau Inhibitor
Oligomerix BIO Europe presentation video, October 2021

Novel, First-In-Class Small Molecule Inhibitors Targeting Tau for Neurodegeneration
Video Presentation: BIO Virtual, June 2021

Novel, First-In-Class Small Molecule Inhibitors Targeting Tau for Neurodegeneration
Slide Deck: BIO Virtual, June 2021

Publications

Davidowitz EJ, Lopez P, Patel, D, Jimenez H, Wolin A, Eun J, Adrien L, Koppel J, Morgan D, Davies P, Moe JG. Therapeutic Treatment with OLX-07010 Inhibited Tau Aggregation and Ameliorated Motor Deficits in an Aged Mouse Model of Tauopathy. 


Davidowitz EJ, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG. Small molecule inhibitor of tau self-association in a mouse model of tauopathy: A preventive study in P301L tau JNPL3 mice. PLoS One. 2023 Aug 9;18(8):e0286523. doi: 10.1371/journal.pone.0286523. PMID: 37556474; PMCID: PMC10411817.


Davidowitz EJ, Krishnamurthy PK, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG. In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice. J Alzheimers Dis. 2020;73(1):147-161. doi: 10.3233/JAD-190465. PMID: 31771053; PMCID: PMC6957711.


Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D'Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep. 2016 Jan 20; 6:19393. doi: 10.1038/srep19393. PMID: 26786552; PMCID: PMC4726138.


Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR. Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging. 2015 Mar;36(3):1342-55. doi: 10.1016/j.neurobiolaging.2014.12.002. Epub 2014 Dec 11. PMID: 25616912; PMCID: PMC4346425.


Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int J Cell Biol. 2013; 2013:260787. doi: 10.1155/2013/260787. Epub 2013 Sep 17. PMID: 24159335; PMCID: PMC3789488.


Davidowitz EJ, Chatterjee I, Moe JG. Targeting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Current Topics in Biotechnology, 4:47-64. 2008. https://api.semanticscholar.org/CorpusID:42627699.


Davidowitz EJ, Chatterjee I, Moe JG (2008) Targeting tau oligomers for therapeutic development for Alzheimer’s disease and tauopathies. Curr Topics Biotechnol 4, 47-64.


Abstracts

Moe, James G. et al. In vivo efficacy of a small molecule inhibitor of tau oligomer formation in htau mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2018, Volume 14, Issue 7, P1527 – P1528.


Moe, James G. et al. CNS drug-like inhibitors of tau oligomerization. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2017, Volume 13, Issue 7, P1580.


Moe, James G. et al. Small molecule tau oligomerization inhibitors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2016, Volume 12, Issue 7, P434.


Krishnamurthy, Pavan K. et al. Characterization of tool compounds targeting tau oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2015, Volume 11, Issue 7, P906.


Moe, James G. et al. Drug development of inhibitors of tau oligomer formation for Alzheimer’s disease and tauopathies. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2014, Volume 10, Issue 4, P865 – P866.


Moe, James et al. Small-molecule lead identification for inhibition of tau oligomer formation. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P891.


Davidowitz, Eliot et al. Characterization of a novel monoclonal antibody specific for a tau autoproteolytic cut site that differentiates between Alzheimer’s disease and non-Alzheimer’s specimens. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2013, Volume 9, Issue 4, P308.


Moe, James G. et al. Extracellular oligomeric tau inhibits memory formation in mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2010, Volume 6, Issue 4, S277.


Moe, James G. et al. Modulation of synaptic function by extracellular tau enriched in oligomers. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2009, Volume 5, Issue 4 , P499.


Media Coverage

    Media Kit

    Coming Soon!

    Archive News

      Oligomerix, Inc.
      1300 Morris Park Ave
      Bronx, N.Y. 10461

      917-912-4088

      • About
      • Management
      • Board of Directors
      • Scientific Advisory Board
      • Pipeline
      • OLX07010 in Rare Tauopathies
      • OLX07010 Alzheimer’s
      • Technology
      • MOA
      • Patents
      • Therapeutic Areas
      • News & Publications
      • Partners and Collaborators
      • Contact Us
      • Site Map
      © Copyright 2026 Oligomerix. All Rights Reserved.
      FCOI Policy
      Website by Axxiem
      Scroll to top
      close ×